However, drastic survival differences still exist by tumor subtype, with 5‐year survival near 95% ER/PR+HER2− tumors but just over 75% for triple‐negative breast cancers (TNBC), for which limited targeted therapies exist.2, 3. Here, ERBB2 is linked to neoplasm.